Core Insights - Zealand Pharma has entered into an agreement with DCAI to utilize the Gefion AI supercomputer to enhance drug discovery and support its Metabolic Frontier 2030 strategy [1][2][3] Company Overview - Zealand Pharma A/S is a biotechnology company focused on developing medicines for obesity and metabolic health, leveraging over 25 years of peptide research expertise [5][6] - The company has more than ten drug candidates in clinical development, with two products already on the market and three in late-stage development [6] Partnership with DCAI - The collaboration with DCAI will allow Zealand Pharma to integrate enterprise-scale artificial intelligence into its drug discovery workflows, improving the quality and efficiency of medicine creation [2][4] - Gefion's infrastructure, powered by over 1,500 NVIDIA GPUs and renewable energy, provides scalable computational power for large-scale protein-peptide simulations [3][7] Strategic Goals - Zealand Pharma aims to deliver more than 10 clinical programs and achieve industry-leading cycle times from idea to clinic by 2030 as part of its Metabolic Frontier 2030 strategy [4][7] - The integration of DCAI's AI capabilities is expected to reduce development timelines and contribute to innovative metabolic treatments [4][7]